[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 1,844
Citations 0
In This Issue of JAMA Neurology
February 2016


JAMA Neurol. 2016;73(2):141. doi:10.1001/jamaneurol.2015.2437

Itrat et al test whether telemedicine is reliable and remote physician presence is adequate for acute stroke treatment using mobile stroke treatment units (MSTUs). They compared the evaluation and treatment of patients on the MSTU with a control group of patients brought to the emergency department via ambulance during the same year. They found that an MSTU using telemedicine is feasible, with a low rate of technical failure, and may provide an avenue for reducing the high cost of such systems. Editorial perspective is provided by Martin Ebinger, MD, and Heinrich J. Audebert, MD.


Continuing Medical Education

Auriel and coauthors test the sensitivity and specificity of clinical and neuroimaging-based criteria for cerebral amyloid angiopathy–related inflammation (CAA-ri). They measured prespecified criteria for probable CAA-ri and possible CAA-ri. Their data suggest that a reliable diagnosis of CAA-ri can be reached from basic clinical and magnetic resonance imaging information alone, with good sensitivity and excellent specificity.

Lehallier and colleagues optimize prediction of progression from mild cognitive impairment (MCI) to Alzheimer disease (AD) dementia by combining information from diverse patient variables. They determine whether combinations of markers could predict progression from MCI to AD within 1 to 6 years. Their study findings suggest that a combination of markers measured in plasma and cerebrospinal fluid, distinct from β-amyloid and tau, could prove useful in predicting midterm progression from MCI to AD dementia.

Clinical Review & Education

Longbrake and Cross hypothesize that the unequivocal success of B-cell–depleting agents in reducing magnetic resonance imaging and clinical activity in therapeutic trials indicates that B cells play a vital role in mediating the clinical course of relapsing multiple sclerosis (MS). They examine the effects of MS disease-modifying therapies (DMTs) on B-cell immunity and report that most DMTs induced B-cell production of the anti-inflammatory cytokine interleukin 10 while inhibiting B-cell expression of proinflammatory cytokines.